\-\ Texto\\:\\ \ \(0\)\
\-\ pertinent\\ physical\\ exam\\ findings\\ included\\:\ \(0\)\
\-\ \\Â\\»\\ splenomegaly\\ to\\ 1\\ cm\\ below\\ the\\ costal\\ margin\ \(1\)\
\-\ \\Â\\»\\ mild\\ tenderness\\ to\\ palpation\\ in\\ the\\ left\\ upper\\ quadrant\ \(1\)\
\-\ \\Â\\»\\ 1\\-2\\ cm\\ firm\\ immobile\\ nodule\\ left\\ midclavicular\\ costovertebral\\ margin\ \(1\)\
\-\ \\Â\\»\\ midline\\ tenderness\\ to\\ t12\\ and\\ l1\ \(0\)\
\-\ \\Â\\»\\ decreased\\ range\\ of\\ motion\\ in\\ flexion\\ secondary\\ to\\ pain\\.\ \(1\)\
\-\ wbc\\:\\ 9\\.39\\ hgb\\:11\\.2\\ hct\\:35\\.7\\ plt\\:535\\ esr\\:117\ \(0\)\
\-\ the\\ patient\\ was\\ placed\\ on\\ amphotericin\\ b\\ and\\ fluconazole\\ and\\ was\\ discharged\\ from\\ the\\ hospital\\.\\ however\\,\\ he\\ returned\\ to\\ the\\ hospital\\ one\\ month\\ later\\ with\\ worsening\\ back\\ pain\\.\\ imaging\\ demonstrated\\ progressive\\ disease\\.\\ he\\ was\\ placed\\ on\\ multiple\\ antifungal\\ therapies\\ with\\ no\\ success\\.\\ the\\ patient\\ was\\ then\\ placed\\ on\\ interferon\\ gamma\\ and\\ posaconazole\\ with\\ noted\\ improvement\\.\ \(0\)\
\-\ the\\ frontal\\ and\\ lateral\\ views\\ of\\ the\\ thoracic\\ spine\\ demonstrate\\ a\\ mixed\\ lucent\\/sclerotic\\ appearance\\ of\\ the\\ t12\\ vertebral\\ body\\ and\\ the\\ left\\ pedicle\\.\\ \ \(0\)\
\-\ a\\ sagittal\\ view\\ mri\\ with\\ gadolinium\\ of\\ the\\ thoracic\\ spine\\ and\\ lumbar\\ spine\\ demonstrates\\ enhancing\\ lesions\\ multiple\\ vertebrae\\,\\ including\\ t12\\.\\ \\ soft\\ tissue\\ enhancement\\ is\\ also\\ present\\ from\\ t9\\-l2\\ paraspinal\\ muscles\\.\\ \ \(0\)\
\-\ a\\ sagittal\\ nonconstrast\\ ct\\ obtained\\ several\\ weeks\\ later\\ demonstrates\\ worsening\\ expansile\\ lytic\\ lesions\\ to\\ t10\\,\\ t11\\,\\ and\\ t12\\.\ \(0\)\
\-\ mri\\ of\\ the\\ thoracic\\ spine\\ was\\ obtained\\ five\\ months\\ after\\ the\\ patient\\ began\\ treatment\\.\\ \\ interval\\ worsening\\ present\\ at\\ multiple\\ levels\\,\\ including\\ multiple\\ compression\\ deformities\\ and\\ enhancing\\ mass\\ with\\ cortical\\ disruption\\ and\\ contiguous\\ anterior\\ soft\\ tissue\\ mass\\ lifting\\ the\\ anterior\\ longitudinal\\ ligament\\.\\ \\ involvment\\ of\\ the\\ posterior\\ elements\\ is\\ present\\ with\\ narrowing\\ of\\ multiple\\ neural\\ foramina\\ and\\ spinal\\ cord\\ compression\\.\ \(0\)\
\-\ disseminated\\ coccidioidomycosis\ \(1\)\
\-\ \\-osteomyelitis\\,\\ including\\ mycobacterial\\ and\\ fungal\\.\ \(0\)\
\-\ \\-metastatic\\ disease\ \(3\)\
\-\ \\-multiple\\ myeloma\ \(0\)\
\-\ the\\ patient\\ is\\ a\\ 23\\ year\\ old\\ man\\ who\\ presented\\ with\\ four\\ weeks\\ of\\ persistent\\ mid\\ back\\ pain\\.\\ he\\ received\\ pain\\ medications\\ with\\ minimal\\ relief\\.\\ his\\ pain\\ gradually\\ worsened\\ over\\ three\\ months\\ to\\ involve\\ his\\ left\\ leg\\ and\\ hip\\.\\ the\\ patient\\ had\\ associated\\ fevers\\,\\ weight\\ loss\\,\\ night\\ sweats\\,\\ fatigue\\,\\ and\\ intermittent\\ abdominal\\ pain\\.\ \(0\)\
\-\ coccidioidomyocosis\\ is\\ a\\ common\\ fungal\\ infection\\ in\\ the\\ southwestern\\ united\\ states\\.\\ it\\ usually\\ leads\\ to\\ a\\ self\\ limited\\ pulmonary\\ infection\\.\\ however\\,\\ in\\ less\\ than\\ 5\\%\\ of\\ cases\\,\\ the\\ infection\\ can\\ disseminate\\ to\\ the\\ soft\\ tissue\\,\\ meninges\\,\\ and\\ bone\\.\\ those\\ who\\ are\\ most\\ susceptible\\ to\\ dissemination\\ include\\ the\\ immunocompromised\\,\\ pregnant\\ women\\,\\ and\\ certain\\ ethnic\\ groups\\,\\ such\\ as\\ latinos\\,\\ filipinos\\,\\ and\\ african\\ americans\\.\\ the\\ most\\ common\\ antifunals\\ used\\ to\\ treat\\ disseminated\\ coccidioidomycosis\\ includes\\ amphotericin\\ b\\ and\\ the\\ azoles\\.\\ the\\ patient\\ was\\ initially\\ placed\\ on\\ amphotericin\\ b\\ and\\ fluconazole\\,\\ but\\ his\\ disease\\ progressed\\.\\ he\\ was\\ placed\\ on\\ itraconazole\\ and\\ posaconazole\\ with\\ no\\ improvement\\.\\ he\\ was\\ then\\ placed\\ on\\ interferon\\ gamma\\ because\\ it\\ was\\ believed\\ that\\ his\\ immune\\ system\\ was\\ unable\\ to\\ recognize\\ coccidiodes\\.\\ he\\ was\\ also\\ placed\\ on\\ posaconazole\\,\\ after\\ which\\ he\\ improved\\.\\ he\\ was\\ discharged\\ from\\ the\\ hospital\\.\\ he\\ will\\ require\\ lifelong\\ antifungal\\ therapy\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ posaconazole\\:\\ 0\\.05257764467574452\ \(0\)\
\-\ t12\\:\\ 0\\.04970631464417464\ \(0\)\
\-\ placed\\:\\ 0\\.048136232693959044\ \(0\)\
\-\ he\\:\\ 0\\.04265941566261864\ \(0\)\
\-\ \\Â\\»\\:\\ 0\\.04185236817075951\ \(0\)\
\-\ amphotericin\\:\\ 0\\.03775712787780416\ \(0\)\
\-\ fluconazole\\:\\ 0\\.02865240760052643\ \(0\)\
\-\ antifungal\\:\\ 0\\.027927470992995793\ \(0\)\
\-\ interferon\\:\\ 0\\.027927470992995793\ \(0\)\
\-\ coccidioidomycosis\\:\\ 0\\.025896355192733405\ \(0\)\
\-\ b\\:\\ 0\\.024024015991159754\ \(0\)\
\-\ was\\:\\ 0\\.02357719734903428\ \(0\)\
\-\ \\-\\-\\:\\ 0\\.023410552459710205\ \(0\)\
\-\ spine\\:\\ 0\\.022378557025887456\ \(0\)\
\-\ multiple\\:\\ 0\\.021468858888420702\ \(0\)\
\-\ disseminated\\:\\ 0\\.020694236625535878\ \(0\)\
\-\ gamma\\:\\ 0\\.020588199857813568\ \(0\)\
\-\ worsening\\:\\ 0\\.020066480936784082\ \(0\)\
\-\ thoracic\\:\\ 0\\.019646466239190367\ \(0\)\
\-\ his\\:\\ 0\\.01958559862939906\ \(0\)\
\-\ hospital\\:\\ 0\\.01918745406541624\ \(0\)\
\-\ including\\:\\ 0\\.018402099250454815\ \(0\)\
\-\ 9\\.39\\:\\ 0\\.017525881558581504\ \(0\)\
\-\ hgb\\:11\\.2\\:\\ 0\\.017525881558581504\ \(0\)\
\-\ hct\\:35\\.7\\:\\ 0\\.017525881558581504\ \(0\)\
\-\ plt\\:535\\:\\ 0\\.017525881558581504\ \(0\)\
\-\ esr\\:117\\:\\ 0\\.017525881558581504\ \(0\)\
\-\ lucent\\/sclerotic\\:\\ 0\\.017525881558581504\ \(0\)\
\-\ t9\\-l2\\:\\ 0\\.017525881558581504\ \(0\)\
\-\ nonconstrast\\:\\ 0\\.017525881558581504\ \(0\)\
\-\ coccidioidomyocosis\\:\\ 0\\.017525881558581504\ \(0\)\
\-\ southwestern\\:\\ 0\\.017525881558581504\ \(0\)\
\-\ latinos\\:\\ 0\\.017525881558581504\ \(0\)\
\-\ filipinos\\:\\ 0\\.017525881558581504\ \(0\)\
\-\ antifunals\\:\\ 0\\.017525881558581504\ \(0\)\
\-\ azoles\\:\\ 0\\.017525881558581504\ \(0\)\
\-\ fungal\\:\\ 0\\.016471926797234956\ \(0\)\
\-\ coccidiodes\\:\\ 0\\.016147855354684996\ \(0\)\
\-\ margin\\:\\ 0\\.015983013432881735\ \(0\)\
\-\ improvement\\:\\ 0\\.01585369656725327\ \(0\)\
\-\ discharged\\:\\ 0\\.015577250990121616\ \(0\)\
\-\ disseminate\\:\\ 0\\.015341761700394408\ \(0\)\
\-\ ethnic\\:\\ 0\\.015341761700394408\ \(0\)\
\-\ infection\\:\\ 0\\.01481520819526525\ \(0\)\
\-\ midclavicular\\:\\ 0\\.013963735496497896\ \(0\)\
\-\ sagittal\\:\\ 0\\.013552074165035304\ \(0\)\
\-\ americans\\:\\ 0\\.01339180294689197\ \(0\)\
\-\ itraconazole\\:\\ 0\\.01339180294689197\ \(0\)\
\-\ lifelong\\:\\ 0\\.01339180294689197\ \(0\)\
\-\ involvment\\:\\ 0\\.013157641842207312\ \(0\)\
\-\ immobile\\:\\ 0\\.012948177596366702\ \(0\)\
\-\ costovertebral\\:\\ 0\\.012948177596366702\ \(0\)\
\-\ dissemination\\:\\ 0\\.012948177596366702\ \(0\)\
\-\ compression\\:\\ 0\\.01271867724174921\ \(0\)\
\-\ pain\\:\\ 0\\.012448606372136\ \(0\)\
\-\ costal\\:\\ 0\\.01242657866104366\ \(0\)\
\-\ susceptible\\:\\ 0\\.01242657866104366\ \(0\)\
\-\ soft\\:\\ 0\\.012411094019842247\ \(0\)\
\-\ t10\\:\\ 0\\.012279246708451767\ \(0\)\
\-\ t11\\:\\ 0\\.012279246708451767\ \(0\)\
\-\ later\\:\\ 0\\.012268066166969875\ \(0\)\
\-\ immunocompromised\\:\\ 0\\.012142083942076118\ \(0\)\
\-\ then\\:\\ 0\\.012091319596111687\ \(0\)\
\-\ tissue\\:\\ 0\\.012080046849617854\ \(0\)\
\-\ obtained\\:\\ 0\\.012078990460214082\ \(0\)\
\-\ l1\\:\\ 0\\.011893250655885252\ \(0\)\
\-\ meninges\\:\\ 0\\.011893250655885252\ \(0\)\
\-\ mycobacterial\\:\\ 0\\.011779615638310802\ \(0\)\
\-\ recognize\\:\\ 0\\.011779615638310802\ \(0\)\
\-\ splenomegaly\\:\\ 0\\.011570151392470193\ \(0\)\
\-\ present\\:\\ 0\\.011510986603966288\ \(0\)\
\-\ therapies\\:\\ 0\\.011380667933614676\ \(0\)\
\-\ self\\:\\ 0\\.011380667933614676\ \(0\)\
\-\ \\,\\:\\ 0\\.011302010687600467\ \(0\)\
\-\ immune\\:\\ 0\\.011292294648185583\ \(0\)\
\-\ back\\:\\ 0\\.011209011273747424\ \(0\)\
\-\ pedicle\\:\\ 0\\.011048552457147148\ \(0\)\
\-\ certain\\:\\ 0\\.010901220504555255\ \(0\)\
\-\ groups\\:\\ 0\\.010901220504555255\ \(0\)\
\-\ lifting\\:\\ 0\\.01083145644926446\ \(0\)\
\-\ enhancing\\:\\ 0\\.010655878858388704\ \(0\)\
\-\ united\\:\\ 0\\.010457595154029989\ \(0\)\
\-\ success\\:\\ 0\\.010347118312767939\ \(0\)\
\-\ tenderness\\:\\ 0\\.010333647407084028\ \(0\)\
\-\ foramina\\:\\ 0\\.010294099928906784\ \(0\)\
\-\ patient\\:\\ 0\\.01021779639264081\ \(0\)\
\-\ believed\\:\\ 0\\.01019212518857368\ \(0\)\
\-\ to\\:\\ 0\\.0101885035811448\ \(0\)\
\-\ on\\:\\ 0\\.010074029993157051\ \(0\)\
\-\ pregnant\\:\\ 0\\.010002641729718164\ \(0\)\
\-\ myeloma\\:\\ 0\\.009871512569098288\ \(0\)\
\-\ gradually\\:\\ 0\\.009871512569098288\ \(0\)\
\-\ progressed\\:\\ 0\\.009829656884808365\ \(0\)\
\-\ vertebrae\\:\\ 0\\.009788664266115051\ \(0\)\
\-\ contiguous\\:\\ 0\\.009788664266115051\ \(0\)\
\-\ 1\\-2\\:\\ 0\\.009748499838048413\ \(0\)\
\-\ sweats\\:\\ 0\\.009670526253250636\ \(0\)\
\-\ weeks\\:\\ 0\\.00964325151849363\ \(0\)\
\-\ deformities\\:\\ 0\\.009595495780123704\ \(0\)\
\-\ treat\\:\\ 0\\.009595495780123704\ \(0\)\
\-\ pertinent\\:\\ 0\\.009559016379192896\ \(0\)\
\-\ leads\\:\\ 0\\.009488006274616198\ \(0\)\
\-\ however\\:\\ 0\\.009460707974541035\ \(0\)\
\-\ worsened\\:\\ 0\\.009353170098992418\ \(0\)\
\-\ elements\\:\\ 0\\.009320843019724466\ \(0\)\
\-\ months\\:\\ 0\\.009280084670735853\ \(0\)\
\-\ cm\\:\\ 0\\.009113145597681852\ \(0\)\
\-\ lesions\\:\\ 0\\.009095668017272157\ \(0\)\
\-\ paraspinal\\:\\ 0\\.009079568950133477\ \(0\)\
\-\ fatigue\\:\\ 0\\.009079568950133477\ \(0\)\
\-\ common\\:\\ 0\\.008891718536605952\ \(0\)\
\-\ longitudinal\\:\\ 0\\.00889008549127796\ \(0\)\
\-\ african\\:\\ 0\\.008864432598960052\ \(0\)\
\-\ who\\:\\ 0\\.008858721308714521\ \(0\)\
\-\ anterior\\:\\ 0\\.00875066729130313\ \(0\)\
\-\ returned\\:\\ 0\\.00869357289756696\ \(0\)\
\-\ relief\\:\\ 0\\.008670320333425427\ \(0\)\
\-\ began\\:\\ 0\\.008602151201261149\ \(0\)\
\-\ neural\\:\\ 0\\.008602151201261149\ \(0\)\
\-\ five\\:\\ 0\\.008472448374485004\ \(0\)\
\-\ firm\\:\\ 0\\.008331104593801642\ \(0\)\
\-\ expansile\\:\\ 0\\.008331104593801642\ \(0\)\
\-\ interval\\:\\ 0\\.008331104593801642\ \(0\)\
\-\ disease\\:\\ 0\\.008330442591743762\ \(0\)\
\-\ disruption\\:\\ 0\\.008273475295842892\ \(0\)\
\-\ night\\:\\ 0\\.00825463087446209\ \(0\)\
\-\ women\\:\\ 0\\.00825463087446209\ \(0\)\
\-\ improved\\:\\ 0\\.008092616889867291\ \(0\)\
\-\ 23\\:\\ 0\\.008075404041471439\ \(0\)\
\-\ fevers\\:\\ 0\\.008075404041471439\ \(0\)\
\-\ gadolinium\\:\\ 0\\.008058338944669466\ \(0\)\
\-\ involve\\:\\ 0\\.008008005330386585\ \(0\)\
\-\ states\\:\\ 0\\.007991506716440867\ \(0\)\
\-\ osteomyelitis\\:\\ 0\\.007895290929439178\ \(0\)\
\-\ received\\:\\ 0\\.007895290929439178\ \(0\)\
\-\ unable\\:\\ 0\\.007848874698828858\ \(0\)\
\-\ most\\:\\ 0\\.007844274917407856\ \(0\)\
\-\ included\\:\\ 0\\.007833640359374446\ \(0\)\
\-\ flexion\\:\\ 0\\.007818521871531068\ \(0\)\
\-\ mri\\:\\ 0\\.007806265824710217\ \(0\)\
\-\ ligament\\:\\ 0\\.007803517486570068\ \(0\)\
\-\ require\\:\\ 0\\.007773844225701925\ \(0\)\
\-\ muscles\\:\\ 0\\.007759172044195717\ \(0\)\
\-\ those\\:\\ 0\\.007730148586101974\ \(0\)\
\-\ it\\:\\ 0\\.0076375681293559304\ \(0\)\
\-\ lytic\\:\\ 0\\.007604544407927955\ \(0\)\
\-\ left\\:\\ 0\\.0076032228172796396\ \(0\)\
\-\ medications\\:\\ 0\\.007577678167039839\ \(0\)\
\-\ from\\:\\ 0\\.007553294511854149\ \(0\)\
\-\ mixed\\:\\ 0\\.007461080300078591\ \(0\)\
\-\ demonstrates\\:\\ 0\\.007421953088084238\ \(0\)\
\-\ below\\:\\ 0\\.0073748965210058\ \(0\)\
\-\ four\\:\\ 0\\.0073748965210058\ \(0\)\
\-\ intermittent\\:\\ 0\\.007292294129528916\ \(0\)\
\-\ lumbar\\:\\ 0\\.007224124997364638\ \(0\)\
\-\ limited\\:\\ 0\\.0071690502408053225\ \(0\)\
\-\ and\\:\\ 0\\.007157415734879461\ \(0\)\
\-\ mid\\:\\ 0\\.0071049133377869885\ \(0\)\
\-\ after\\:\\ 0\\.00702982585530498\ \(0\)\
\-\ levels\\:\\ 0\\.007012428217240483\ \(0\)\
\-\ nodule\\:\\ 0\\.007002412722151105\ \(0\)\
\-\ views\\:\\ 0\\.007002412722151105\ \(0\)\
\-\ initially\\:\\ 0\\.006914473845457614\ \(0\)\
\-\ the\\:\\ 0\\.0068712368142955175\ \(0\)\
\-\ includes\\:\\ 0\\.0068486687790036485\ \(0\)\
\-\ range\\:\\ 0\\.006839443372330681\ \(0\)\
\-\ motion\\:\\ 0\\.00683026057738775\ \(0\)\
\-\ narrowing\\:\\ 0\\.00681202126073558\ \(0\)\
\-\ persistent\\:\\ 0\\.006776037082517652\ \(0\)\
\-\ hip\\:\\ 0\\.006767141892865721\ \(0\)\
\-\ vertebral\\:\\ 0\\.006723253320899122\ \(0\)\
\-\ progressive\\:\\ 0\\.0067145906859707805\ \(0\)\
\-\ also\\:\\ 0\\.0066982886428236625\ \(0\)\
\-\ minimal\\:\\ 0\\.0066888269789280265\ \(0\)\
\-\ system\\:\\ 0\\.0066888269789280265\ \(0\)\
\-\ leg\\:\\ 0\\.006680312740772955\ \(0\)\
\-\ midline\\:\\ 0\\.006572823235265448\ \(0\)\
\-\ used\\:\\ 0\\.006517264725542667\ \(0\)\
\-\ cord\\:\\ 0\\.0064556141554779345\ \(0\)\
\-\ view\\:\\ 0\\.006373850156623336\ \(0\)\
\-\ wbc\\:\\ 0\\.006192991750647737\ \(0\)\
\-\ cortical\\:\\ 0\\.006192991750647737\ \(0\)\
\-\ weight\\:\\ 0\\.006089355437655795\ \(0\)\
\-\ spinal\\:\\ 0\\.006083054096182079\ \(0\)\
\-\ quadrant\\:\\ 0\\.005978878596393746\ \(0\)\
\-\ because\\:\\ 0\\.00594337637492256\ \(0\)\
\-\ less\\:\\ 0\\.0057533598495480755\ \(0\)\
\-\ three\\:\\ 0\\.005726887133890478\ \(0\)\
\-\ palpation\\:\\ 0\\.005669859006656166\ \(0\)\
\-\ cases\\:\\ 0\\.005659663745489329\ \(0\)\
\-\ body\\:\\ 0\\.005517422888049869\ \(0\)\
\-\ several\\:\\ 0\\.00546141716843417\ \(0\)\
\-\ frontal\\:\\ 0\\.005336564482074269\ \(0\)\
\-\ will\\:\\ 0\\.00531507160711559\ \(0\)\
\-\ such\\:\\ 0\\.005310800775031515\ \(0\)\
\-\ usually\\:\\ 0\\.005158903089198328\ \(0\)\
\-\ month\\:\\ 0\\.005096649186482324\ \(0\)\
\-\ decreased\\:\\ 0\\.005051205572017017\ \(0\)\
\-\ demonstrated\\:\\ 0\\.004984930382618225\ \(0\)\
\-\ 5\\:\\ 0\\.004970497857741875\ \(0\)\
\-\ pulmonary\\:\\ 0\\.004963320696262551\ \(0\)\
\-\ loss\\:\\ 0\\.00493134030311817\ \(0\)\
\-\ appearance\\:\\ 0\\.004858661186351175\ \(0\)\
\-\ include\\:\\ 0\\.004765712699861404\ \(0\)\
\-\ secondary\\:\\ 0\\.004749562557671585\ \(0\)\
\-\ a\\:\\ 0\\.004730812745351108\ \(0\)\
\-\ mass\\:\\ 0\\.004725491081302443\ \(0\)\
\-\ presented\\:\\ 0\\.004630929691893457\ \(0\)\
\-\ one\\:\\ 0\\.004603839728251777\ \(0\)\
\-\ enhancement\\:\\ 0\\.004553655598654146\ \(0\)\
\-\ therapy\\:\\ 0\\.004542029415985313\ \(0\)\
\-\ \\:\\:\\ 0\\.0044941344572193434\ \(0\)\
\-\ mild\\:\\ 0\\.00447366491835216\ \(0\)\
\-\ is\\:\\ 0\\.004471497243616108\ \(0\)\
\-\ than\\:\\ 0\\.004451389373594977\ \(0\)\
\-\ over\\:\\ 0\\.004325333181192768\ \(0\)\
\-\ metastatic\\:\\ 0\\.004276559450529006\ \(0\)\
\-\ abdominal\\:\\ 0\\.0042463603143580815\ \(0\)\
\-\ bone\\:\\ 0\\.0042215401221866195\ \(0\)\
\-\ physical\\:\\ 0\\.004168002524018366\ \(0\)\
\-\ upper\\:\\ 0\\.004099563628963654\ \(0\)\
\-\ 1\\:\\ 0\\.004042398345844347\ \(0\)\
\-\ noted\\:\\ 0\\.004026682283205951\ \(0\)\
\-\ man\\:\\ 0\\.004017757143320077\ \(0\)\
\-\ associated\\:\\ 0\\.00400887189246064\ \(0\)\
\-\ imaging\\:\\ 0\\.0039802660525956315\ \(0\)\
\-\ \\%\\:\\ 0\\.00396286487742745\ \(0\)\
\-\ posterior\\:\\ 0\\.003915782402986975\ \(0\)\
\-\ demonstrate\\:\\ 0\\.0039094475970835795\ \(0\)\
\-\ can\\:\\ 0\\.0038533247563997406\ \(0\)\
\-\ exam\\:\\ 0\\.0037320754273350654\ \(0\)\
\-\ lateral\\:\\ 0\\.0036713082417983104\ \(0\)\
\-\ had\\:\\ 0\\.0036657054060451454\ \(0\)\
\-\ but\\:\\ 0\\.003623267000066675\ \(0\)\
\-\ findings\\:\\ 0\\.0036159780035585677\ \(0\)\
\-\ treatment\\:\\ 0\\.0034386023053695563\ \(0\)\
\-\ no\\:\\ 0\\.0034212491081662103\ \(0\)\
\-\ in\\:\\ 0\\.003351071412646162\ \(0\)\
\-\ which\\:\\ 0\\.003171261604855961\ \(0\)\
\-\ that\\:\\ 0\\.0029343553251666467\ \(0\)\
\-\ as\\:\\ 0\\.002569736592234846\ \(0\)\
\-\ ct\\:\\ 0\\.0023763492115149954\ \(0\)\
\-\ are\\:\\ 0\\.0023158526292835022\ \(0\)\
\-\ at\\:\\ 0\\.002301716009605632\ \(0\)\
\-\ with\\:\\ 0\\.002093514085107371\ \(0\)\
\-\ of\\:\\ 0\\.0020845610480753397\ \(0\)\
\-\ \\.\\:\\ 0\\.0020466929360299048\ \(0\)\
\-\ year\\:\\ 0\\.0019008057043199099\ \(0\)\
\-\ old\\:\\ 0\\.0017394325981356948\ \(0\)\
